Lifotronic(688389)2024-07-24 07:34Group 1: Equity Incentive Plans - The company has implemented three phases of equity incentive plans, with performance targets set for a revenue growth rate of 60% and 90% for 2024-2025, and a net profit growth rate of 60% and 90% [2][3] - The company is confident in achieving the performance assessment targets set in the equity incentive plans through continuous product iteration and market channel expansion [2][3] Group 2: Research and Development Investments - In 2023, the company's R&D expenditure was 170 million CNY, accounting for 15% of its revenue [3] - The company focuses on in vitro diagnostics and treatment and rehabilitation, with ongoing R&D in biochemical immunoassay products and clinical medical product upgrades [3] Group 3: Product Development Focus - The in vitro diagnostics product line emphasizes the development of mid-speed luminescence instruments and new testing reagents [3] - The clinical medical product line is upgrading existing products in respiratory critical care, wound treatment, and pain rehabilitation to obtain more international product registrations [3] - The skincare and beauty product line is developing new products focused on anti-aging, skin whitening, and hair growth treatments [3] Group 4: Investor Relations Activity - The investor relations activity involved 10 institutions and 20 participants, held on July 18 and 23, 2024, in Beijing and online [2][4] - The meeting was attended by the board secretary, Lu Man, who addressed investor inquiries regarding the equity incentive plans and R&D projects [2][3]